Hyperfine

Hyperfine, Inc. is a medical device development company engaged in the development of, MRI solutions and non-invasive neural monitoring technology. The company was founded by Jonathan M. Rothberg on February 25, 2014 and is headquartered in Guilford, CT.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hyperfine reports Q4 revenue of $1.4M, eyes $14M revenue in 2023

Hyperfine's Q4 2022 earnings call highlighted financial performance, strategic achievements in 2022, challenges in net losses and expenses, and opportunities for revenue growth and expansion in 2023. The company's focus on innovation, partnerships, and commercial progress underpins its outlook for the coming year.

Hyperfine reports record revenue in Q1 2023, eyes U.S. expansion

Hyperfine's Q1 2023 performance reflects strong revenue growth and strategic advancements in FDA clearances and partnerships. While facing significant expenses and cash burn, the company maintains a positive outlook for revenue and growth opportunities through innovation and market expansion.

Hyperfine reports record revenue in Q2 2023 amidst strategic expansion

Hyperfine's Q2 2023 earnings call reflects strong revenue growth, strategic focus on critical care and pediatric markets, and ongoing investment in technology and clinical studies. Despite financial challenges, the company maintains a positive outlook with a clear roadmap for future growth. Managing expenses and cash burn while pursuing innovation will be key to sustainable success.

Hyperfine reports robust Q3 earnings, eyes market expansion opportunities

Hyperfine's Q3 performance showcased strong revenue growth and improved financial metrics.
The company's focus on innovation and collaborations presents opportunities for market expansion.
Challenges include balancing investments in clinical studies while maintaining financial stability.

Hyperfine reports strong revenue growth and innovation focus for 2024

Hyperfine's Q4 2023 performance reflects robust revenue growth, strategic expansion into prestigious institutions, and a focus on cutting-edge healthcare solutions.
While facing financial challenges and a net loss, the company's commitment to innovation, FDA clearances, and market opportunities position it for future success.
With a strong 2024 revenue guidance, Hyperfine is poised to leverage its achievements in 2023, customer success, and international expansion to drive growth and profitability.

Hyperfine reports strong Q1 revenue growth and advances in medical imaging

Hyperfine's Q1 2024 performance reflects revenue growth driven by international contributions and advancements in clinical programs and commercial expansion.
While facing financial challenges and cash burn, the company maintains a positive outlook with plans for future growth and innovation in medical imaging technology.
Strategic strengths in AI software development and clinical applications position Hyperfine well to capture opportunities in the healthcare market and drive revenue growth.

Hyperfine reports robust Q3 growth, eyes international expansion opportunities

Hyperfine's Q3 2024 performance reflects strong revenue growth and operational efficiency improvements.
The company's focus on innovation, clinical efficacy, and market expansion presents opportunities for sustained growth.
However, managing cash burn, meeting revenue targets, and navigating competitive pressures remain key challenges for Hyperfine.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. It also develops imaging of health conditions through its Swoop portable magnetic resonance. The company was founded by Jonathan M. Rothberg and Ronald Walsworth on February 25, 2014 and is headquartered in Guilford, CT.

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. announces presentations on clinical advancements at RSNA 2023.

Hyperfine, Inc. Announces Presentations on Clinical Advancements at RSNA 2023

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to present at the Piper Sandler 35th annual healthcare conference.

Hyperfine, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference

Hyperfine, Inc. (NASDAQ:HYPR ) Q3 2023 Earnings Call November 9, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations Maria Sainz - President and Chief Executive Officer Brett Hale - Chief Administrative Officer and Chief Financial Officer Conference Call Participants Neil Chatterji - B. Riley Operator Good afternoon, and welcome to Hyperfine's Third Quarter 2023 Earnings Conference Call.

Hyperfine, Inc. (HYPR) Q3 2023 Earnings Call Transcript

GUILFORD, Conn., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world's first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced third quarter 2023 financial results and provided a business update.

Hyperfine, Inc. Reports Third Quarter 2023 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Observational study finds that Hyperfine, Inc. portable MR brain imaging system assists clinicians in early detection of ABI in ECMO patients.

Observational Study Finds That Hyperfine, Inc. Portable MR Brain Imaging System Assists Clinicians in Early Detection of Acute Brain Injury in ECMO Patients

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. to announce third quarter financial results on November 9, 2023.

Hyperfine, Inc. to Announce Third Quarter Financial Results on November 9, 2023

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. announces promotions of two key clinical affairs executives.

Hyperfine, Inc. Announces Promotions of Two Key Clinical Affairs Executives

Hyperfine's (HYPR) updated Swoop software is expected to make brain imaging more accessible and clinically relevant.

Hyperfine (HYPR) Progresses in MRI Space With Latest FDA Nod

ING Groep NV

Successful investing is about anticipating others' anticipation. The value of a stock is based on what people think it's worth. Selling shares of Hyperfine may be a great opportunity for buyers.

Hyperfine: Swoop-Ing In On The Low-Field MRI Opportunity

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. receives FDA clearance for updated AI-powered software with improved image quality for all Swoop® system sequences.

Hyperfine, Inc. Receives FDA Clearance for Updated AI-powered Software with Improved Image Quality for All Swoop® System Sequences

Hyperfine, Inc. (HYPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -21.28% in 4 Weeks, Here's Why Hyperfine, Inc. (HYPR) Looks Ripe for a Turnaround

Hyperfine, Inc. (HYPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -15.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Hyperfine, Inc. (HYPR)

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance brain imaging system, today announced plans to participate at the upcoming Gilmartin Group Emerging Growth Showcase, taking place virtually. Members of management are scheduled to present on Thursday, September 21, 2023, at 1:00 pm ET. Interested parties can register and access a live webcast of the.

Hyperfine, Inc. to Present at Gilmartin Group Emerging Growth Showcase

The heavy selling pressure might have exhausted for Hyperfine, Inc. (HYPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Hyperfine, Inc. (HYPR) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Hyperfine, Inc. (HYPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Hyperfine, Inc. (HYPR) Upgraded to Buy: Here's What You Should Know

Hyperfine Inc. (NASDAQ:HYPR ) Q2 2023 Results Conference Call August 14, 2023 4:30 PM ET Company Participants Marissa Bych - IR Maria Sainz - CEO, President & Director Brett Hale - Chief Administrative Officer and CFO Conference Call Participants Neil Chatterji - B. Riley Operator Good afternoon.

Hyperfine Inc. (HYPR) Q2 2023 Earnings Call Transcript

GUILFORD, Conn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable, point-of-care MRI system, today announced second quarter 2023 financial results and provided a business update.

Hyperfine, Inc. Reports Second Quarter 2023 Financial Results

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance brain imaging system, today announced completed enrollment for the multi-site observational study, HOPE PMR (Portable MRI for Children with Neurological Injury—A Pilot Study using Hydrocephalus as an Index Condition). Children living with hydrocephalus typically undergo at least two brain scans per y.

Enrollment Completed for HOPE PMR Pediatric Hydrocephalus Study Using Hyperfine, Inc. Portable MR Imaging® System

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the second quarter 2023 on Monday, August 14, 2023. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Invest.

Hyperfine, Inc. to Announce Second Quarter Financial Results on August 14, 2023

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance brain imaging system, today announced the promotion of Tom Teisseyre, Ph.D. to chief operating officer. Dr. Teisseyre will oversee product design and development, clinical science, operations, cybersecurity, and technical service. Dr. Teisseyre has served as chief product officer since June 2021 and.

Hyperfine, Inc. Announces Promotion of Tom Teisseyre, Ph.D. to Chief Operating Officer

Hyperfine's (HYPR) ACTION PMR study focuses on utilizing point-of-care brain imaging to identify strokes and salvageable brain tissue.

Hyperfine (HYPR) ACTION PMR Study Targets Better Stroke Care

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance brain imaging system, has announced the commencement of an international, multi-site observational study, ACTION PMR (ACuTe Ischemic strOke detectioN with Portable MR). To support its acute stroke care initiatives, Hyperfine Inc. has formed an advisory board of world-renowned stroke experts. As a pro.

Hyperfine, Inc. Launches Observational Study to Define New Imaging Paradigm in Stroke Care

TORONTO--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance brain imaging system, is proud to be the first magnetic resonance imaging technology partner in an education-centric collaboration between the International Society for Magnetic Resonance in Medicine (ISMRM) and the Bill & Melinda Gates Foundation. The ISMRM, a non-profit organization, has long promoted.

Hyperfine, Inc. and the International Society for Magnetic Resonance in Medicine Collaborate to Enhance Global Access to MR Education

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance imaging (MRI) system, today announced an expansion of clinical research to study the neurological effects of early childhood malnutrition in low and middle-income countries, with funding support from the Bill & Melinda Gates Foundation. The goal of the collaborative, multi-year global study is to.

Hyperfine, Inc. Receives Grant for an Additional Three Years to Utilize Innovative Swoop® Portable MR Imaging® System in Low and Middle-Income Countries

Hyperfine, Inc. (NASDAQ:HYPR ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Maria Sainz - President, Chief Executive Officer Brett Hale - Chief Administrative Officer, Incoming Chief Financial Officer Marissa Bych - Investor Relations, The Gilmartin Group Conference Call Participants Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Neil Chatterji - B. Riley Operator At this time all participants are in listen-only mode.

News for Hyperfine Stock (HYPR)